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A POSSIBLE RELATIONSHIP between his-
tamine H2-receptor antagonism and anti-
tumour drug activity has been suggested
by Collins (1980, 1981). This work demon-
strated that the activity of at least 1 anti-
cancer drug, razoxane, could be enhanced
by prior administration of H2-receptor
antagonists. Structural analogues having
no such antagonist activity were devoid
of this effect.
Recently, similar findings were reported
by Dorr & Alberts (1982) using cyclo-
phosphamide and cimetidine but we have
been unable to obtain any potentiation
with this combination using the Walker
carcinoma. A direct anti-tumour effect
of cimetidine has also been reported
(Gifford et al., 1981; Osband et al., 1981),
though again such an effect could not be
demonstrated in the present studies.
Although the relationship of H2-recep-
tor antagonism to anti-tumour activity is
unclear, H2-receptor antagonists have
other activities, such as the inhibition of
the microsomal P450 system by cimeti-
dine (Pelkonen & Puurunen, 1980), which
suggest that they would influence the
metabolism of other drugs and this indeed
has been shown to be the case (Serlin
et al., 1979; Desmond et al., 1980a, b). It is
also believed that cimetidine interferes
with suppressor-cell function (Daman &
Rosenberg, 1977; Jorizzo et al., 1980), and
that this action is responsible for its direct
anti-tumour effect (Osband et al., 1981).
The purpose ofthe present study was to
enlarge on the initial findings of enhance-
ment of razoxane anti-tumour activity in
cimetidine-pretreated animals by examin-
ing this effect with a wider spectrum of
tumours, a larger number of anti-tumour
agents and structural analogues of H2-
receptor antagonists.
Six-week old female Sprague-Dawley
rats weighing 200 g were used in all
experiments. Walker tumour mash (0 3
ml) was injected s.c. on Day 0 and
animals were dosed on Days 1, 2, 3 and 4.
The end-point of reduction of tumour
weight on Day 8 was used to assess the
anti-tumour effect of chemotherapeutic
agents. All drugs were given orally and
H2-receptor antagonists given 1 h before
administration of anti-cancer agents.
Sarcoma 180 tumour mash (0-1 ml) was
injected s.c. into the flanks of male
Schneider mice on Day 0. Animals were
dosed with razoxane at 2-5 mg/kg on
Days 1, 2, 3, 6 and 7 and reduction of
tumour weight used to assess anti-
tumour effect.
L1210 cell suspension (5 x 105 cells in
041 ml) was injected s.c. into the flanks of
male BDF mice on Day 0. Animals were
dosed with razoxane 50, 100, 150, 200 or
250 mg/kg on Day 2 and increase in
life-span used to assess anti-tumour effect.
Lewis lung carcinoma tumour mash
(0.1 ml) was injected s.c. into the flanks of
C57B1 female mice on Day 0. Animals
were dosed with razoxane 75 or 100 mg/kg
on Day 3 and reduction of Day 21 tumour
weight was used to assess chemothera-
peutic response.M. COLLINS AND K. HELLMANN
TLX5 cell suspension (2 x 106 cells in
0-1 ml) was injected s.c. into the flanks of
female CBA mice. Animals were dosed
with razoxane 150 mg/kg on Day 3 and
increase in life-span used to assess anti-
tumour activity.
All drugs were given orally and cimeti-
dine given 1 h before administration of
razoxane except where stated.
Cimetidine, metiamide and SKF 91581
(Smith, Kline and French Laboratories,
Welwyn Garden City, Herts.) were dis-
solved in HC1 and neutralized with NaOH.
Ranitidine and AH 19659 (Glaxo Group
Research, Ware, Herts.) were dissolved
in sterile water. Cyclophosphamide, in
parenteral powdered form (WB Pharma-
ceuticals, Bracknell, Berks.), was dis-
solved in sterile water. Methotrexate
(Lederle Laboratories Division, New York,
U.S.A.) was dissolved in HC1 and neutra-
lized with NaOH. 5-Fluorouracil (Roche
Products, Welwyn Garden City, Herts)
was obtained in solution suitable for oral
administration. Razoxane (Imperial
Chemical Industries, Macclesfield, Ches-
hire) was ball-milled overnight and sus-
pended in carboxymethylcellulose (0.5%
in isotonic saline).
The direct cytotoxic effect of cimeti-
dine in vitro was assessed after incubation
with L1210 cells in suspension, either
alone or in combination with razoxane,
and cell counts were determined by
Coulter counter at various times after
incubation. The L1210 cells were cultured
in 3024F Falcon flask in RPM1 medium
supplemented with 10% foetal calf serum
(Gibco Europe Ltd, Paisley, Scotland).
The direct cytotoxic effect of cimetidine
in vivo was determined in all experiments
in animals bearing tumours or L1210
leukaemia cells which were treated only
with this agent.
The end-point of reduction of tumour
weight for solid tumours or increased
survival time for leukaemias was used to
assess the anti-tumour activity of the
chemotherapeutic agents. Comparison of
animals treated with cimetidine plus
chemotherapeutic agents vs control ani-
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Fia. 1. Enhancement of razoxane anti-
tumour activity (50 mg/kg) by the active
H2-receptor antagonists cimetidine (200
mg/kg), metiamide (200 mg/kg) and rani-
tidine (40 mg/kg). No enhancement was
seen with the structural analogues SKF
91581 (200 mg/kg) and AH19659 (40
mg/kg), which were devoid of H2 antagon-
ist activity. S denotes significant enhance-
ment.
mals receiving chemotherapeutic agent
alone was analysed by Student's t test,
and the significance level taken as P<
0-05.
Rats pretreated with cimetidine demon-
strated a significantly greater anti-tumour
effect in response to the anti-tumour
agent razoxane than rats not pretreated
with cimetidine (Fig. 1). Cimetidine alone
possessed no anti-tumour activity even
at doses up to 400 mg/kg, nor were any
visible signs of toxicity noted up to this
dose level either alone or in combination
with the anti-cancer agent.
The enhancement of anti-tumour acti-
vity occurred with the active H2-receptor
antagonists metiamide, which is a struc-
tural analogue of cimetidine, and also
with ranitidine, another type of H2-
receptor antagonist (Fig. 1). Again, no
anti-tumour activity was seen with H2-
receptor antagonists alone. No enhance-
ment was obtained by pretreatment with
structural analogues SKF 91581 and
AH 19659, which are devoid of H2-
antagonist activity (Fig. 1). No anti-
tumour activity was seen with these
inactive analogues alone.
The combination of cimetidine with an
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FIG. 2. Cimetidine pretreatment (200 mg/kg)
(lid not pro(luce enlhancement of the anti-
tumour activity of cyclophosphamidte
(0.7 mg/kg), methotrexate (0-5 mg/kg) or
5-fluorouracil (25 mg/kg) against the
WAalker tumour.
ED20-ED50 dose of the anti-cancer agents
cyclophosphamide, methotrexate or 5-
fluorouracil has failed to demonstrate
any enhancement (Fig. 2).
Pretreatment with cimetidine of mice
bearing sarcoma 180, leukaemia L1210,
Lewis lung carcinoma or lymphoma TLX5
gave no enhancement of razoxane activity
against these tumours.
Incubation of L1210 cells with cimeti-
dine failed to demonstrate any direct
cytotoxic effect of the drug either alone
or in the presence of razoxane.
A link between H2-receptor antagonism
and anti-tumour drug activity was sug-
gested by Collins (1980, 1981) and there
is some evidence to support this theory.
Firstly there was the chance observation
by Armitage & Sidner (1979) of significant
regression of pulmonary lesions in 2
patients receiving cimetidine therapy.
Then Gifford et al. (1981) demonstrated a
reduction in tumour formation and an
increase in survival time in tumour-
bearing mice treated with cimetidine,
and Osband et al. (1981) reported a slow-
ing of metastatic development and pro-
longed survival in response to cimetidine.
Also Dorr & Alberts (1982) have demon-
strated an enhancement of cyclophospha-
mide anti-tumour activity by cimetidine
in mice, although we have been unable
to show any potentiation in this combina-
tion in rats.
Early studies with H2-receptor antago-
nists revealed no significant interactions
with other compounds (Lesley & Walker,
1977), but a number of reports have now
appeared suggesting that the H2-receptor
antagonist, cimetidine, significantly inter-
feres with the action of other drugs. These
include the anticoagulants (Serlin et al.,
1979), the methylxanthines (Desmond
et al., 1980b), minor tranquillizers (Des-
mond et al., 1980a; Klotz et al., 1979)
and the barbiturates (Pelkonen &
Puurunen, 1980; Dorr & Alberts, 1982).
Although the mechanism of H2-receptor
involvement in anti-tumour drug activity
remains obscure, Gifford et al. (1981)
and Osband et al. (1981) have suggested
inhibition of suppressor-cell function by
cimetidine, while Dorr & Alberts (1982)
explain their results through an inter-
ference with the microsomal metabolism
of compounds utilizing the P450 system
as previously suggested by Pelkonen &
Puurunen (1979, 1980), or via a change
in liver blood flow as demonstrated for
cimetidine by Feely et al. (1981).
Both Gifford et al. (1981) and Osband
et al. (1981) demonstrated a direct anti-
tumour effect of cimetidine in vivo
reflected by prolonged survival of tumour-
bearing animals and a slowing of
metastatic development. However, we
have been unable to detect any direct
anti-tumour effect of cimetidine in the
Walker tumour or against any mouse
tumour. We have also been unable to
demonstrate a direct cytotoxic effect of
cimetidine against L1210 cells in vitro
which was in agreement with the in vitro
results of Gifford et al. (1981) using EL4
cells.
Our results show a significant enhance-
ment by cimetidine of the anti-tumour
activity of only 1 anti-cancer agent,
razoxane. This enhancement was specific
to active H2-receptor antagonists, and
structural analogues having no such
antagonist activity were devoid of this
effect. Thus H2-antagonism appears to
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be a prerequisite for enhancement of
anti-tumour activityinthese experiments.
However, unlike Dorr & Alberts (1982),
we were unable to demonstrate any
enhancement of cyclophosphamide anti-
tumour activity by cimetidine, and this
discrepancy may be attributed to the
use of a different tumour system, or
the fact that Dorr & Alberts administered
the drug i.p. directly to the site of the
tumour. In our experiments both drugs
were administered by the more thera-
peutically relevant oral route. We were
also unable to demonstrate any enhance-
ment of the anti-tumour activity of
methotrexate or 5-fluorouracil.
Whilst cimetidine has been reported
to reduce the oxidative metabolism of
many drugs by inhibition of the P450
enzyme system, ranitidine has no such
activity (Henry et al., 1980). It therefore
seems unlikely that the H2-antagonist-
potentiating effect of the anti-tumour
action of razoxane is mediated through
this mechanism. However, cimetidine has
been reported to reduce liver blood flow
(Feely et al., 1981) and it could therefore
be that it might have an effect on tumour
blood vessels. Since it had earlier been
shown that razoxane normalizes the
development ofthetumourneovasculature
(Le Serve & Hellmann, 1972) it may be
possible that the 2 drugs interact at this
level.
In conclusion, we have demonstrated
an interaction between several H2-receptor
antagonists and at least one anti-cancer
agent, leading to enhancement of anti-
cancer activity of this agent by an as yet
unknown mechanism. The H2-antagonists
demonstrated no direct anti-tumour acti-
vity either in vivo or in vitro. The inter-
action between H2-receptor antagonists
was specific to activate antagonists and
did not occur with analogues devoid of
antagonist activity.
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